Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,898,032
  • Shares Outstanding, K 3,181,976
  • Annual Sales, $ 30,238 M
  • Annual Income, $ 712,320 K
  • EBIT $ 2,182 M
  • EBITDA $ 11,532 M
  • 60-Month Beta 0.03
  • Price/Sales 1.72
  • Price/Cash Flow 5.15
  • Price/Book 1.07

Options Overview Details

View History
  • Implied Volatility 36.24% (+2.08%)
  • Historical Volatility 15.60%
  • IV Percentile 82%
  • IV Rank 34.25%
  • IV High 72.40% on 10/29/25
  • IV Low 17.40% on 03/24/25
  • Expected Move (DTE 4) 1.14 (6.98%)
  • Put/Call Vol Ratio 4.46
  • Today's Volume 2,032
  • Volume Avg (30-Day) 498
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 11,697
  • Open Int (30-Day) 7,638
  • Expected Range 15.17 to 17.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.55
  • Number of Estimates 1
  • High Estimate 0.55
  • Low Estimate 0.55
  • Prior Year 0.42
  • Growth Rate Est. (year over year) +30.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.40 +14.86%
on 12/15/25
16.54 unch
on 01/12/26
+2.21 (+15.42%)
since 12/12/25
3-Month
12.99 +27.33%
on 10/30/25
16.54 unch
on 01/12/26
+2.83 (+20.64%)
since 10/10/25
52-Week
12.80 +29.22%
on 01/23/25
16.54 unch
on 01/12/26
+3.59 (+27.72%)
since 01/10/25

Most Recent Stories

More News
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera ...

PTGX : 80.52 (+0.37%)
TAK : 16.32 (+0.06%)
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants...

TAK : 16.32 (+0.06%)
British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)

TORONTO , Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLA TM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for...

TAK : 16.32 (+0.06%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 80.52 (+0.37%)
KPTI : 8.26 (-4.84%)
GTBP : 0.6999 (+3.38%)
GSK : 50.41 (+0.04%)
TAK : 16.32 (+0.06%)
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals ...

TAK : 16.32 (+0.06%)
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose 1 ...

TAK : 16.32 (+0.06%)
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied...

TAK : 16.32 (+0.06%)
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic...

TAK : 16.32 (+0.06%)
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation

Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the...

TAK : 16.32 (+0.06%)
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program ...

TAK : 16.32 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 16.57
2nd Resistance Point 16.47
1st Resistance Point 16.39
Last Price 16.32
1st Support Level 16.21
2nd Support Level 16.12
3rd Support Level 16.04

See More

52-Week High 16.54
Last Price 16.32
Fibonacci 61.8% 15.11
Fibonacci 50% 14.67
Fibonacci 38.2% 14.23
52-Week Low 12.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar